China’s National Medical Products Administration has accepted the supplemental new drug application seeking the approval of cadonilimab plus chemotherapy for use in the first-line treatment of patients with unresectable locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.